

January 28, 2017

Dept of Corporate Services  
Bombay Stock Exchange Limited  
Floor 25, P J Towers  
Dalal Street  
Mumbai – 400 001.

Dear Sirs,

**Sub: Unaudited Results for the Quarter and nine months ended – Reg**  
**Ref: 1) Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements)**  
**Regulations 2016 – Reg**  
**2) Our letter dated**  
**3) Ref Scrip Code 526783**


We request your kind attention to the above subject and references. We wish to inform you that the Board Meeting held today, the Board of Directors of the Company have taken on record and approved the Unaudited Financial Results for the Quarter and Nine months ended 31<sup>st</sup> December 2016. We enclose herewith the Financial Results and the Auditors' Limited review Report.

As per the listing regulations, the Company has also made arrangement for release of the Unaudited Results in the News Papers.

Kindly acknowledge the receipt.

Thanking you,

Yours faithfully,




**HEMA PASUPATHEESWARAN**  
**COMPANY SECRETARY & COMPLIANCE OFFICER**  
**DR. AGARWAL'S EYE HOSPITAL LTD**

## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS


### TO THE BOARD OF DIRECTORS OF DR. AGARWAL'S EYE HOSPITAL LIMITED

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **DR. AGARWAL'S EYE HOSPITAL LIMITED** ("the Company") for the Quarter and Nine Months ended 31 December 2016 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting AS - 25 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS**  
Chartered Accountants  
(Firm's Registration No. 008072S)

  
**Sriraman Parthasarathy**  
Partner  
(Membership No. 206834)

Chennai, 28 January 2017  
PS/RB/2017





**Dr. Agarwal's Eye Hospital Limited**

Regd Office: 3rd Floor, Buhari Towers, No.4, Moores Road, Off Greaves Road, Chennai - 600 006

Phone No. 91-44-39916669, Website : [www.dragarwal.com](http://www.dragarwal.com), E-mail : [investor@dragarwal.com](mailto:investor@dragarwal.com), CIN : L85110TN1994PLC027366


Statement of Unaudited Financial Results for the Quarter and Nine Months Ended 31 December 2016

Rs. In Lacs

S.NO	Particulars	Quarter Ended			Year to date figures for the Period Ended			Year Ended
		31-Dec-16 Unaudited	30-Sep-16 Unaudited	31-Dec-15 Unaudited	31-Dec-16 Unaudited	31-Dec-15 Unaudited	31-Mar-16 Audited	
1	<b>Income from Operations</b>							
	(a) Net Sales/Income from Operations	3,415.29	3,393.77	2,830.69	11,183.91	10,057.10	13,466.70	
	(b) Other Operating Income	-	-	18.12	-	66.48	189.19	
	<b>Total Income from Operations (net)</b>	<b>3,415.29</b>	<b>3,393.77</b>	<b>2,848.81</b>	<b>11,183.91</b>	<b>10,123.58</b>	<b>13,655.89</b>	
2	<b>Expenses</b>							
	(a) Purchase of Stock-in-trade	500.27	520.82	310.40	1,498.09	1,339.04	1,778.04	
	(b) Changes in Inventories of Stock-in-trade	(23.37)	62.84	49.58	83.15	(41.40)	18.96	
	(c) Consumables	356.11	419.53	283.73	1,368.83	1,185.09	1,566.26	
	(d) Consultancy Charges	506.20	516.05	471.44	1,518.98	1,487.48	1,973.92	
	(e) Employee Benefit Expenses	829.47	843.35	750.14	2,427.68	2,062.79	2,926.14	
	(f) Depreciation and Amortisation Expense	208.14	198.87	223.80	601.72	590.49	852.62	
	(g) Rent	401.80	380.46	390.82	1,142.20	1,142.20	1,456.96	
	(h) Other Expenditure	599.14	634.22	541.54	1,764.79	1,711.38	2,242.18	
	(i) Prior Period Items	-	-	-	-	542.43	542.43	
	<b>Total Expenses</b>	<b>3,377.76</b>	<b>3,576.14</b>	<b>3,021.45</b>	<b>10,445.86</b>	<b>10,009.50</b>	<b>13,357.51</b>	
3	<b>Profit / (Loss) from Operations before Other Income, Finance Cost &amp; Exceptional Items (1-2)</b>	<b>37.53</b>	<b>385.63</b>	<b>(172.64)</b>	<b>738.05</b>	<b>114.08</b>	<b>298.38</b>	
4	<b>Other Income</b>	2.33	25.55	5.52	31.16	15.78	27.83	
5	<b>Profit / (Loss) from Ordinary Activities before Finance Cost &amp; Exceptional Items (3+4)</b>	<b>39.86</b>	<b>381.18</b>	<b>(167.12)</b>	<b>769.21</b>	<b>129.86</b>	<b>326.21</b>	
6	<b>Finance Costs</b>	81.10	81.89	100.89	252.80	283.01	374.36	
7	<b>Profit / (Loss) from Ordinary Activities after Finance Cost but before Exceptional Items (5-6)</b>	<b>(41.24)</b>	<b>299.29</b>	<b>(268.01)</b>	<b>516.41</b>	<b>(153.15)</b>	<b>(48.15)</b>	
8	<b>Exceptional Items</b>	-	-	-	-	-	-	
9	<b>Profit / (Loss) from Ordinary Activities before Tax (7-8)</b>	<b>(41.24)</b>	<b>299.29</b>	<b>(268.01)</b>	<b>516.41</b>	<b>(153.15)</b>	<b>(48.15)</b>	
10	<b>Tax Expenses</b>							
	- relating to the current period	(12.92)	98.94	(89.77)	171.46	107.75	135.93	
	- relating to the prior years	-	-	-	-	(187.75)	(187.75)	
11	<b>Net Profit / (Loss) from Ordinary Activities after Tax (9-10)</b>	<b>(28.32)</b>	<b>200.35</b>	<b>(178.24)</b>	<b>344.95</b>	<b>(73.15)</b>	<b>3.67</b>	
12	<b>Extraordinary Items (net of tax expense)</b>	-	-	-	-	-	-	
13	<b>Net Profit / (Loss) for the period (11-12)</b>	<b>(28.32)</b>	<b>200.35</b>	<b>(178.24)</b>	<b>344.95</b>	<b>(73.15)</b>	<b>3.67</b>	
14	<b>Paid-up equity share capital (Face value of Rs.10 each)</b>	470.00	470.00	470.00	470.00	470.00	470.00	
15	<b>Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year</b>	-	-	-	-	-	1,872.11	
16	<b>Earnings Per Share (EPS) (of Rs. 10 each not annualised)</b>							
	(a) Basic	(0.60)	4.26	(3.79)	7.34	(1.56)	0.08	
	(b) Diluted	(0.60)	4.26	(3.79)	7.34	(1.56)	0.08	
17	<b>Dividend per share (Face Value of Rs. 10 each)</b>	-	-	-	-	-	-	
	- Final dividend on equity shares (in Rs. per share)	-	-	-	-	-	0.80	



119-7





**Dr. Agarwal's Eye Hospital Limited**

Regd Office: 3rd Floor, Buhari Towers, No.4, Moores Road, Off Greams Road, Chennai - 600 006


Phone No. 91-44-39916669, Website : [www.dragarwal.com](http://www.dragarwal.com), E-mail : [investor@dragarwal.com](mailto:investor@dragarwal.com), CIN : L85110TN1994PLC027366

**Statement of Unaudited Financial Results for the Quarter and Nine Months Ended 31 December 2016**

**Notes:**

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its Meeting held on 28 January 2017. The Statutory Auditors of Company have carried out a Limited Review of the above Unaudited Financial Results for the Quarter and Nine Months Ended 31 December 2016.
- 2 The Company has identified the business segment which is "Eye Care related Sales and Services" as its primary segment. The amounts appearing in the results relate to this segment.
- 3 The Company has paid capital advances / deposits amounting to Rs. 187 Lacs as at 31 December 2016 relating to opening of new hospitals in identified locations.
- 4 Previous period / year figures have been regrouped wherever necessary, to conform with the current period presentation.

By the Order of the Board

  
Dr. Arun Agarwal  
Chairman & Managing Director  
DIN NO. 00435684

Place : Chennai  
Date : 28 January 2017

